Cellectar Corp - CLRB Company Short-Term Debt

Cellectar Corp (CLRB) - corporate logo

Cellectar Biosciences (CLRB) attracts rare radiochemists through premium bonuses and scientific prestige. The company's short-term debt dynamics illustrate working capital management, where the value of 0.00 expresses the metric level. Efficient isotope aviation logistics support the business, although the expansion of pharma behemoths into radiopharmaceuticals intensifies the struggle for patents and specialized laboratories.

CLRB (Cellectar Biosciences, Inc.) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

Cellectar Corp - analytical breakdowns and key metrics (CLRB)

- price and consensus price forecast:
Stock Price Cellectar Biosciences, Inc.|CLRB - Average Forecast Price
- market capitalization data:
Market Value Cellectar Biosciences, Inc.|CLRB - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Cellectar Biosciences|CLRB - Book Capitalization|Market Value to Book Value Ratio cellectar.com|CLRB - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Cellectar Biosciences|CLRB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cellectar Biosciences|CLRB - Company Cumulative Debt|Debt to Book Capitalization Ratio Cellectar Biosciences, Inc.|CLRB - Company Long-Term Indebtedness|Company Short-Term Debts Cellectar Biosciences
Fundamental company valuation:Cellectar Biosciences
Signature product of Cellectar Biosciences

Portfolio managers are evaluating the operating model of Cellectar Biosciences (CLRB) through the lens of short-term liquidity, where this metric measures the speed of meeting current obligations and the inertia of the credit load. An analysis of short-term liabilities confirms the financial stability of the radiopharmaceutical aviation logistics, ensuring that the express delivery of isotopes is supported by stable capital without the need for emergency asset sales to cover debts.

Competitors of Cellectar Biosciences (CLRB)

INCY (Incyte) - Company Short-Term Debts|HCM: Short-Term Debt|Company Short-Term Debt Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc (DAWN) - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts INBX|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt Fennec Pharma FENC|Company Current Liabilities Heron Therapeutics, Inc.|Nuvectis Pharma, Inc - Company Short-Term Loans and Borrowings|CHRS (Coherus BioSciences, Inc.) - Company Short-Term Debt|CRBP: Short-Term Debt|Company Short-Term Debt cardiffoncology.com|BeyondSpring, Inc. (BYSI) - Company Short-Term Indebtedness|Company Short-Term Debts BCAB|Company Current Liabilities LIXT|Citius Pharmaceuticals - Company Short-Term Debt|Short-Term Debt BLRX (biolinerx.com)|Company Short-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Short-Term Debt|KZIA (Kazia) - Company Short-Term Debt|SLXN - Short-Term Debt|Company Short-Term Debts NCNA (nucana.com)|Short-Term Indebtedness chimerix.com|Company Current Liabilities CYCC (Cyclacel)|Short-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Current Liabilities|Company Short-Term Loans and Borrowings Kintara Pharma KTRA|Company Current Liabilities Oncternal Therapeutics (ONCT)|Amount of Current Liabilities portagebiotech.com PRTG